Skip to main content
SYNAIRGEN PLC logo

SYNAIRGEN PLC — Investor Relations & Filings

Ticker · SNG ISIN · GB00B0381Z20 LEI · 213800IMMTOPPDF8HD24 IL Manufacturing
Open in API
Filings indexed 379 across all filing types
Latest filing 2026-04-30 Regulatory Filings
Country GB United Kingdom
Listing IL SNG

About SYNAIRGEN PLC

https://www.synairgen.com/

Synairgen PLC is a clinical-stage biotechnology company focused on the discovery and development of treatments for severe respiratory diseases. The company's primary focus is its lead investigative candidate, SNG001, an inhaled formulation of interferon-beta (IFN-β). SNG001 is being developed as a potential host-directed, broad-spectrum antiviral therapy delivered directly to the lungs. This approach aims to treat hospitalized patients with severe viral lung infections caused by a range of pathogens, including influenza, RSV, and coronaviruses.

Recent filings

Filing Released Lang Actions
Corporate Update
Regulatory Filings
2026-04-30 English
Corporate Update
Regulatory Filings Classification · 98% confidence The document is a corporate announcement from Synairgen Limited regarding the termination of a clinical study and the subsequent decision to wind down operations. It is distributed via the RNS (Regulatory News Service) platform. While it contains significant strategic information, it does not fit into specific categories like 10-K, ER, or M&A. As it is a general regulatory announcement regarding company status and strategic direction, it falls under the RNS (Regulatory Filings) category.
2026-02-26 English
First Patient Dosed in the INVENT Clinical Study
Regulatory Filings Classification · 98% confidence The document is a press release distributed via the London Stock Exchange's RNS (Regulatory News Service) platform. It announces a specific operational milestone: the dosing of the first patient in a Phase 2 clinical trial (INVENT study). Since this is a general corporate announcement regarding clinical trial progress that does not fit into specific categories like financial reports, dividends, or board changes, it falls under the 'Regulatory Filings' (RNS) category.
2025-12-08 English
Synairgen & Aerogen Announce Strategic Partnership
Regulatory Filings Classification · 100% confidence The document is a press release announcing a strategic partnership between Synairgen PLC and Aerogen Ltd. to develop an inhaled therapy device. It is distributed via the RNS (Regulatory News Service) Reach platform, which is typically used for corporate announcements that do not fall under mandatory regulatory reporting requirements. Since it describes a business development/partnership activity rather than financial results, governance, or specific regulatory filings, it is best classified as a general regulatory announcement.
2025-11-12 English
Group of companies' accounts made up to 2024-12-31
Regulatory Filings
2025-10-03 English
Publication of Annual Report and Accounts 2024
Report Publication Announcement Classification · 100% confidence The document is a short announcement (2331 characters) from Synairgen PLC stating that their Annual Report and Accounts for the year ended 31 December 2024 have been filed with Companies House and published on their website. Per the 'Menu vs Meal' rule, this is an announcement of a report's publication rather than the report itself, making it a Report Publication Announcement (RPA).
2025-09-30 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.